Europe and the United Kingdom undervalue new medicines. If the United States adopted European-style price controls, the world would benefit from fewer new cures–and we’d all be worse off.

Drug development is costly. Who takes the risk and funds the hope of new medicines? Investors do. How do they know which ones will work? They often don't.

At No Patient Left Behind, we believe for insurance to really be insurance it should fully cover the drugs your doctor prescribes when you’re sick–without high out-of-pocket costs.

Who creates new medicines? It takes teams of innovators working with the support of private funding to reach risky new summits and provide patients with new cures.

Under the drug pricing provisions of the Inflation Reduction Act, small molecule treatments will face Medicare “negotiation” (price setting) that makes brand medicines functionally generic just 9 years after FDA approval. This policy will unwisely skew investment towards harder to manufacture biologics and away from small molecule treatments for diseases of aging. Without both kinds of medicines, we will all be worse off.

No Patient Left Behind (NPLB) wrote to the Centers for Medicare and Medicaid services (CMS) urging fixes to its plan for implementation of the Inflation Reduction Act. NPLB suggested fixes that will lower out-of-pocket costs for beneficiaries and protect small molecule innovation.

400+ biotech and pharma executives voice support for the FDA's indispensable role in regulating new medicines. The letter warns that judicial orders undermining the decisions of the FDA would destroy the basic infrastructure necessary for continued medical innovation.

No Patient Left Behind (NPLB) wrote to the Centers for Medicare and Medicaid services (CMS) warning that the exemptions of the Inflation Reduction Act fail to provide adequate protections for orphan drugs and other small molecule treatments.